536 related articles for article (PubMed ID: 34105780)
41. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
[TBL] [Abstract][Full Text] [Related]
42. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
[TBL] [Abstract][Full Text] [Related]
43. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
[TBL] [Abstract][Full Text] [Related]
44. Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease: the GOASIA study.
Pitisuttithum P; Chan WK; Piyachaturawat P; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Fan JG; Song MJ; Yoon SK; Dan YY; Lesmana L; Ho KY; Goh KL; Wong VWS; Treeprasertsuk S
BMC Gastroenterol; 2020 Apr; 20(1):88. PubMed ID: 32252638
[TBL] [Abstract][Full Text] [Related]
45. Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease.
Mosca A; Comparcola D; Romito I; Mantovani A; Nobili V; Byrne CD; Alisi A; Targher G
Liver Int; 2019 Dec; 39(12):2317-2329. PubMed ID: 31436362
[TBL] [Abstract][Full Text] [Related]
46. ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
Daniels SJ; Leeming DJ; Eslam M; Hashem AM; Nielsen MJ; Krag A; Karsdal MA; Grove JI; Neil Guha I; Kawaguchi T; Torimura T; McLeod D; Akiba J; Kaye P; de Boer B; Aithal GP; Adams LA; George J
Hepatology; 2019 Mar; 69(3):1075-1086. PubMed ID: 30014517
[TBL] [Abstract][Full Text] [Related]
47. Serum ferritin levels predict histological severity in patients with nonalcoholic fatty liver disease in India.
Parikh P; Patel J; Ingle M; Sawant P
Indian J Gastroenterol; 2015 May; 34(3):200-8. PubMed ID: 26108652
[TBL] [Abstract][Full Text] [Related]
48. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
49. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience.
Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM
J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423
[TBL] [Abstract][Full Text] [Related]
50. Proteomic screening of plasma identifies potential noninvasive biomarkers associated with significant/advanced fibrosis in patients with nonalcoholic fatty liver disease.
Hou W; Janech MG; Sobolesky PM; Bland AM; Samsuddin S; Alazawi W; Syn WK
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31860081
[TBL] [Abstract][Full Text] [Related]
51. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
[TBL] [Abstract][Full Text] [Related]
52. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
[TBL] [Abstract][Full Text] [Related]
53. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
[TBL] [Abstract][Full Text] [Related]
54. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?
Alkhouri N; Feldstein AE
Metabolism; 2016 Aug; 65(8):1087-95. PubMed ID: 26972222
[TBL] [Abstract][Full Text] [Related]
55. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
[TBL] [Abstract][Full Text] [Related]
56. Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis.
Traussnigg S; Kienbacher C; Gajdošík M; Valkovič L; Halilbasic E; Stift J; Rechling C; Hofer H; Steindl-Munda P; Ferenci P; Wrba F; Trattnig S; Krššák M; Trauner M
Liver Int; 2017 Oct; 37(10):1544-1553. PubMed ID: 28544208
[TBL] [Abstract][Full Text] [Related]
57. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease.
Subasi CF; Aykut UE; Yilmaz Y
Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):137-41. PubMed ID: 25486027
[TBL] [Abstract][Full Text] [Related]
58. Performance of non-invasive models of fibrosis in predicting mild to moderate fibrosis in patients with non-alcoholic fatty liver disease.
Siddiqui MS; Patidar KR; Boyett S; Luketic VA; Puri P; Sanyal AJ
Liver Int; 2016 Apr; 36(4):572-9. PubMed ID: 26713759
[TBL] [Abstract][Full Text] [Related]
59. Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD.
Welsh JA; Scorletti E; Clough GF; Englyst NA; Byrne CD
J Leukoc Biol; 2018 Sep; 104(3):631-639. PubMed ID: 29603349
[TBL] [Abstract][Full Text] [Related]
60. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]